Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sight Sciences’ management is scheduled to participate in a fireside chat Tuesday, September 13, 2022, at 7:20am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a trademark of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

Staff

Recent Posts

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM)…

3 hours ago

Performant Survey Spotlights Top Healthcare Technology Initiatives

PLANTATION, Fla.--(BUSINESS WIRE)--At HIMSS25, Performant Healthcare, Inc. (Nasdaq: PHLT) (the “Company” or “Performant”), a leader…

5 hours ago

IgniteData Appoints Dr. Jose Galvez as Chief Medical Information Officer to Accelerate Clinical Data Innovation

NEW CASTLE, Del., April 17, 2025 /PRNewswire/ -- IgniteData, the leader in eSource to sponsor…

5 hours ago

Ansys to Release First Quarter 2025 Earnings on April 30, 2025

PITTSBURGH, April 17, 2025 /PRNewswire/ -- ANSYS, Inc. (NASDAQ: ANSS) announced today that the Company…

5 hours ago

ERPHealth partners with Penn State to help prevent substance use disorder

PHILADELPHIA, April 17, 2025 /PRNewswire/ -- The Edna Bennett Pierce Prevention Research Center (PRC) at…

5 hours ago

Groundbreaking Study on Omega-3 DHA Enriched Foods to Enhance Public Health in Saudi Arabia

RIYADH, Saudi Arabia, April 17, 2025 /PRNewswire/ -- In a significant advancement for public health,…

5 hours ago